Clifford Chance advises on advanced surgical robotics company Edge Medical’s Chapter 18A IPO and Listing in Hong Kong

Global law firm Clifford Chance has advised the joint sponsors and underwriters including Morgan Stanley, GF Capital, GF Securities, CICC, CLSA and CMBC Securities on the initial public offering and listing of advanced surgical robotics company Shenzhen Edge Medical Co., Ltd. (Edge Medical) on the Main Board of the Hong Kong Stock Exchange, under the Exchange’s Chapter 18A Listing Rules for Biotech Companies.

The listing is expected to raise approximately HK$1.2 billion, backed by several cornerstone investors including Abu Dhabi Investment Authority, UBS, Tencent, OrbiMed and ChinaAMC (Hong Kong).

Founded in 2017 in Shenzhen, Edge Medical is an advanced surgical robotics company in the medical device industry, dedicated to designing, developing and manufacturing surgical robots for minimally invasive surgery, as well as non-invasive surgery. It is the first company in China and second globally to receive registration approvals of all of its multi-part endoscopic, single-port endoscopic and natural orifice surgical robots.

Partner Fang Liu said, “Edge Medical’s listing reflects the depth of China’s medtech sector, showcasing innovation in surgical robotics, as well as the strength of Hong Kong’s biotech listing platform. We leverage deep biotech expertise and proven Chapter 18A experience to guide clients through every stage of these landmark listings. These transactions are vital to scaling life science breakthroughs globally and central to Hong Kong’s strategy to build world class champions.”

Partners Fang Liu and Virginia Lee led the transaction with support from counsel Janet Fok, senior associates Ran Bi and Ryan Ho, associates Ruoyu Xiong, Choo Jun Kai, Phoebe Yan Ting Lo and Grace Wang*, legal assistant Minting Luo, trainee solicitor Carina Tan, paralegals Pascal Chan and Jay Lee.